Meta-Analysis of Epidermal Growth Factor Polymorphisms and Cancer Risk: Involving 9,779 Cases and 15,932 Controls

The epidermal growth factor (EGF) pathway stimulates proliferation and differentiation of epidermal and epithelial tissues, and plays an important role in tumorigenesis. The association between EGF polymorphisms and cancer risk is controversial; thus, we performed this meta-analysis. Overall, 41 case-control studies with 9,779 cases and 15,932 controls were retrieved. We found that EGF + 61A/G polymorphism increased overall cancer risk (G allele vs. Aallele: OR = 1.181, 95% CI = 1.077-1.295, P-heterogeneity < 0.001; GG vs. AA: OR = 1.370, 95% CI = 1.143-1.641, P-heterogeneity < 0.001; GG+GA vs. AA: OR = 1.175, 95% CI = 1.047-1.318, P-heterogeneity < 0.001). In the stratified analysis by cancer type, the + 61G allele was a risk factor for colorectal cancer, esophageal carcinoma, gastric cancer, and hepatocellular carcinoma. Individuals who carried +61G allele had higher cancer susceptibility in mixed and European racial subgroups. An increased association was detected in the hospital-based subgroup. No significant association was found among EGF -1380A/G, -1744G/A, rs6983267T/G polymorphisms and cancer risk.